IL1B and myeloid sarcoma: In the M and MS groups, IL-1β increased significantly at 4 months of treatment (58.19 ± 0.03 pg/mL, 58.35 ± 0.30 pg/mL) when compared to baseline (33.05 ± 18.56 pg/mL, 34.79 ± 18.77 pg/mL), then decreased significantly at 8 months (29.25 ± 11.64 pg/mL, 32.54 ± 14.26 pg/mL) when compared to 4 months (58.19 ± 0.03 pg/mL, 58.35 ± 0.3 pg/mL) (p < 0.05) (Table 2).